Compare TG Therapeutics Inc (TGTX) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs United States Natural Gas Fund — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.36B), while United States Natural Gas Fund trades at $10.05. The key difference: TG Therapeutics Inc is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals.
| TGTX | UNG | |
|---|---|---|
Market Cap | $8.36B | — |
Sector | Health | Commodities - Energy |
52-Week High | $59.06 | $16.90 |
52-Week Low | $26.94 | $9.63 |
Enterprise Value | $8.57B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
UNG trades at $10.46, down 0.95% with a bearish technical signal from moving averages. The ETF faces headwinds from high natural gas production and storage levels, though weather-driven demand provides some support. Recent EIA forecasts project record natural gas supply and demand through 2027, creating a mixed fundamental backdrop for this futures-based commodity ETF.
The outlook remains challenged by oversupply concerns, though long-term demand growth from LNG exports and data center power needs offers potential upside. Key risks include commodity price volatility and the structural limitations of futures-based ETFs versus equity-based alternatives like FCG.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
